A Study to Assess the pharmacoMRI Effects of AUT00206 in Healthy Males
NCT ID: NCT02935725
Last Updated: 2017-11-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
22 participants
INTERVENTIONAL
2016-10-31
2017-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Low dose AUT00206 800 mg + Ketamine
Low dose AUT00206 (800 mg) + ketamine
Low dose AUT00206 800mg
Ketamine
High dose AUT00206 2000 mg + Ketamine
High dose AUT00206 (2000 mg) + ketamine
High dose AUT00206 2000 mg
Ketamine
Placebo + Ketamine
Placebo + ketamine
Placebo
Ketamine
Placebo + Saline
Placebo + saline
Placebo
Saline
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Low dose AUT00206 800mg
High dose AUT00206 2000 mg
Placebo
Ketamine
Saline
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Healthy on the basis of medical history, psychiatric history, physical examination, vital signs, 12-lead electrocardiogram (ECG), haematology, blood chemistry and urinalysis within 6 weeks of Visit 2.
* Right-handed.
* Not a regular smoker (maximum 5 cigarettes per week or equivalent).
Exclusion Criteria
* History of significant claustrophobia.
18 Years
45 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Manchester
OTHER
Autifony Therapeutics Limited
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bill Deakin, Prof
Role: PRINCIPAL_INVESTIGATOR
University of Manchester
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Of Manchester
London, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2016-000216-14
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
AUT021206
Identifier Type: -
Identifier Source: org_study_id